Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease - a prospective observational study
Abstract
Background: Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of PlGF and the development of LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the relationship of PlGF to other CV risk factors in CKD patients.
The aim of our study was to determine the possible association of PlGF and several other CV risk markers to echocardiographic parameters in CKD population. Methods: We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D, parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide - BNP) and echocardiographic parameters in 62 patients with CKD 2-4.
Mean follow-up was 36 +/- 10 months. Laboratory and echocardiographic data were collected 2-3 times, at the shortest interval of 12 months apart.
Multivariate regression analysis was used to detect independent correlations of variables. Results: Increased left ventricular mass index (LVMI, g/m(2.7)) was found in 29% patients with CKD 2-4, left ventricular (LV) diastolic dysfunction was detected in 74.1% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 30.6% patients).
After 36 +/- 10 months increased LVMI was found in 37.1% patients with CKD 2-4, LV diastolic dysfunction was detected in 75.8% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 32.3% patients). Following independent correlations were found: LVMI was related to PlGF, cholesterol, BNP, systolic blood pressure and serum creatinine.